Atlas Trials

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Clinical trial NCT05852717 · RECRUITING

Trial details

NCT number
NCT05852717
Sponsor
Dipenkumar Modi
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Large Cell Lymphoma, DiffuseRelapsed CancerRefractory Cancer
Start date
2023-10-31
Primary completion
2027-11-24
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.